PHOENIX, Nov. 02, 2017 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or “the company”), today reported financial results for its third quarter ended Sept. 30, 2017.
OVERALL HIGHLIGHTS
- Gross revenue was $48.9 million, resulting in net revenue of $30.7 million
- Net revenue was unfavorably impacted by approximately $5 million due to product returns
- Total R&D investment was $19.6 million
- Accrued minimum liability of $150.0 million paid over five years in connection with ongoing Department of Justice (DOJ) investigation
- Net loss totaled $166.3 million, which included DOJ accrual, or ($2.30) per basic and diluted share
- Launched SYNDROS® (dronabinol) oral solution, first and only FDA-approved liquid dronabinol, generating $0.7M of revenue in first two months
- Filed New Drug Application (NDA) for novel formulation of buprenorphine as sublingual spray for management of moderate-to-severe acute pain
- Completed pharmacokinetics (PK) study of proprietary intranasal naloxone spray formulation for treatment of opioid overdose
“Earlier this year, we took meaningful, strategic steps to restore trust with our key stakeholders, including patients, clinicians, regulators, and investors,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “The past few months have only strengthened our commitment to move forward and continue our efforts to address unmet medical needs. In the third quarter, our team soundly executed against the organization’s strategic initiatives and we made strong progress to transform and diversify our business over the long term. This included further work to stabilize our SUBSYS® product through the signing of additional managed care contracts. These wins should help solidify the product’s base revenue beginning in 2018. We also continued to realize the benefits of our strong pipeline as we brought our second commercial product to market and delivered on several of our R&D commitments, including the early filing of our NDA for buprenorphine as a sublingual spray. I am pleased with our progress to date across the business and recognize there is still more to be done.”
Mr. Motahari concluded, “As part of our effort to broaden the company’s capabilities, we’ve expanded and upgraded our fully-integrated manufacturing facility in Round Rock, Texas over the last year. The expansion component of the project is complete, and the related upgrade will be finished by the end of the year. This facility will be a distinct competitive advantage for us when it is complete, as we will be one of the only companies in the United States that can manufacture synthetic cannabinoids ranging from clinical to commercial scale. Further, it will allow us to continue to pursue partnership opportunities with supportive institutions, including those in academia and the scientific community, all of whom are currently looking to further the science of cannabinoids.”
Financial & Operating Highlights
- Net revenue for the third quarter of 2017 was $30.7 million, compared to $57.8 million for the third quarter of 2016. The results reflect a decline in SUBSYS® prescription volumes due to ongoing softness in overall demand in the TIRF category, and was partially offset by $0.7 million in revenues from the recently launched SYNDROS® product.
- Gross margin was 75.6% for the third quarter of 2017, compared to 91.9% in the same period of 2016. Gross margin was negatively impacted by product returns and inventory expiration.
- Sales and marketing investment was $12.8 million during the third quarter of 2017, compared to $16.7 million for the third quarter of 2016. The reduction was driven by cost management in light of lower revenue.
- Research and development investment increased to $19.6 million for the third quarter of 2017, compared to $16.5 million for the same period in 2016, reflecting the company’s commitment to its robust new product pipeline including filing fees associated with our NDA for buprenorphine.
- General and administrative expense decreased to $15.7 million for the third quarter of 2017 from $17.7 million for the third quarter of 2016, driven by a stock compensation charge taken in the third quarter of 2016, and a reduction in outside legal expenses.
- Income tax benefit was $9.0 million for the third quarter of 2017, compared to a benefit of $0.4 million during the third quarter of 2016.
- The company accrued an aggregate reserve of $150.0 million in connection with the DOJ investigation.
- Net loss for the third quarter of 2017 was $166.3 million, or ($2.30) per basic and diluted share, compared to net income of $2.9 million, or $0.04 per basic and diluted share, for the third quarter of 2016.
- Adjusted EBITDA loss for the third quarter of 2017 was $18.4 million, compared to Adjusted EBITDA of $12.2 million in the prior-year quarter. The reconciliation of net income to Adjusted EBITDA is included at the end of this news release.
- The company had $177.2 million in cash, cash equivalents, and short-term and long-term investments; no debt; and $106.0 million in stockholders’ equity as of Sept. 30, 2017.
Webcast Information
A conference call is scheduled for 8:30 a.m. Eastern Standard Time on Nov. 2, 2017, to discuss the financial and operational results for the third quarter of fiscal year 2017. Investors, analysts and members of the media interested in listening to the live presentation are encouraged to join a webcast of the call available through the INVESTORS section of the company’s website at http://www.insysrx.com. Interested parties may also participate in the call by dialing 844-263-8304 (from inside the U.S.) or 213-358-0958 (from outside the U.S.). A replay of the conference call will be available a few hours after the event through the website’s INVESTORS section, under the NEWS & EVENTS tab for “Presentations.”
About INSYS
INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. INSYS currently markets SUBSYS® (fentanyl sublingual spray), CII, and SYNDROS® (dronabinol) oral solution, CII, a proprietary, orally administered liquid formulation of dronabinol. INSYS is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with a significant unmet need.
SUBSYS® and SYNDROS® are trademarks of INSYS Development Company, Inc., a subsidiary of INSYS Therapeutics, Inc.
NOTE: All trademarks and registered trademarks are the property of their respective owners.
Forward-Looking Statements
This news release contains forward-looking statements, including discussions about future revenue and product development, as well as the reserve taken in connection with the DOJ investigation. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
Non-GAAP Financial Measures
In addition to reporting all financial information required in accordance with generally accepted accounting principles (GAAP), the company is also reporting Adjusted EBITDA, Adjusted net income and Adjusted net income per diluted share, which are non-GAAP financial measures. Since Adjusted EBITDA, Adjusted net income and Adjusted net income per diluted share are not GAAP financial measures, they should not be used in isolation or as a substitute for consolidated statements of comprehensive income (loss) and cash flow data prepared in accordance with GAAP. In addition, the company's definitions of Adjusted EBITDA, Adjusted net income and Adjusted net income per diluted share may not be comparable to similarly titled non-GAAP financial measures reported by other companies. For a full reconciliation of Adjusted EBITDA and Adjusted net income to GAAP net income, please see the attachments to this earnings release.
Adjusted EBITDA, as defined by the company, is calculated as follows:
Net income, plus:
- Interest income (expense), net;
- The recorded provision for income taxes;
- Depreciation and amortization; and
- Non-cash expenses, such as stock compensation expense and accrual for expected litigation judgment.
The company believes that Adjusted EBITDA can be a meaningful indicator, to both company management and investors, of the past and expected ongoing operating performance of the company. EBITDA is a commonly used and widely accepted measure of financial performance. Adjusted EBITDA is deemed by the company to be a useful performance indicator because it includes an add-back of non-cash and non-recurring operating expenses that may be subject to uncontrollable factors not reflective of the company's true operational performance.
Adjusted net income, as defined by the company, is calculated as follows:
Net income, plus:
- The recorded provision for income taxes;
- Non-cash expenses, such as stock compensation expense, non-cash interest, and non-cash other expense (i.e., accrual for expected litigation judgment); and;
- Less an estimated cash tax provision, net of the benefit from utilizing NOL carry-forwards and windfalls from employee stock option exercises.
Adjusted net income per diluted share is equal to Adjusted net income divided by the diluted share count for the applicable period.
The company believes that Adjusted net income and Adjusted net income per diluted shares are meaningful financial indicators, to both company management and investors, in that they exclude non-cash income and expense items, as well as other income and expense items that are not expected to recur and therefore are not reflective of continuing operating performance.
While the company uses Adjusted EBITDA, Adjusted net income and Adjusted net income per diluted share in managing and analyzing its business and financial condition and believes these non-GAAP financial measures to be useful to investors in evaluating the company's performance, each of these financial measures has certain shortcomings. Adjusted EBITDA does not take into account the impact of capital expenditures on either the liquidity or the GAAP financial performance of the company and likewise omits share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense. Adjusted net income does not take into account non-cash expenses that reflect the amortization of past expenditures, or include stock-based compensation, which is an important and material element of the company's compensation package for its directors, officers and other key employees. As a result of the inherent limitations of each of these non-GAAP financial measures, the company's management utilizes comparable GAAP financial measures to evaluate the business in conjunction with Adjusted EBITDA, Adjusted net income and Adjusted net income per diluted share and encourages investors to do likewise.
— Financial tables follow —
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||||||||||
| (In thousands, except share and per share amounts) | ||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||||||||||
| Net revenue | $ | 30,670 | $ | 57,773 | $ | 109,208 | $ | 187,415 | ||||||||||||||||
| Cost of revenue | 7,472 | 4,677 | 16,032 | 15,588 | ||||||||||||||||||||
| Gross profit | 23,198 | 53,096 | 93,176 | 171,827 | ||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| Sales and marketing | 12,825 | 16,662 | 41,775 | 56,153 | ||||||||||||||||||||
| Research and development | 19,552 | 16,516 | 46,589 | 58,440 | ||||||||||||||||||||
| General and administrative | 15,714 | 17,653 | 47,882 | 46,275 | ||||||||||||||||||||
| Charges related to litigation award and government settlements | 150,850 | - | 155,300 | - | ||||||||||||||||||||
| Total operating expenses | 198,941 | 50,831 | 291,546 | 160,868 | ||||||||||||||||||||
| Income (loss) from operations | (175,743 | ) | 2,265 | (198,370 | ) | 10,959 | ||||||||||||||||||
| Other income (expense),net | (83 | ) | - | (44 | ) | 44 | ||||||||||||||||||
| Interest income | 510 | 281 | 1,410 | 762 | ||||||||||||||||||||
| Income (loss) before income taxes | (175,316 | ) | 2,546 | (197,004 | ) | 11,765 | ||||||||||||||||||
| Income tax expense (benefit) | (8,996 | ) | (379 | ) | (15,976 | ) | 523 | |||||||||||||||||
| Net income (loss) | $ | (166,320 | ) | $ | 2,925 | $ | (181,028 | ) | $ | 11,242 | ||||||||||||||
| Net income (loss) per common share: | ||||||||||||||||||||||||
| Basic | $ | (2.30 | ) | $ | 0.04 | $ | (2.51 | ) | $ | 0.16 | ||||||||||||||
| Diluted | $ | (2.30 | ) | $ | 0.04 | $ | (2.51 | ) | $ | 0.15 | ||||||||||||||
| Shares used in computing net income per common share: | ||||||||||||||||||||||||
| Basic | 72,285,146 | 71,640,536 | 72,133,417 | 71,592,145 | ||||||||||||||||||||
| Diluted | 72,285,146 | 74,328,963 | 72,133,417 | 74,545,823 | ||||||||||||||||||||
| Percentage of Net revenue: | ||||||||||||||||||||||||
| Net revenue | 100.0 | % | 100.0 | % | 100.0 | % | 100.0 | % | ||||||||||||||||
| Cost of revenue | 24.4 | % | 8.1 | % | 14.7 | % | 8.3 | % | ||||||||||||||||
| Gross profit | 75.6 | % | 91.9 | % | 85.3 | % | 91.7 | % | ||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| Sales and marketing | 41.8 | % | 28.8 | % | 38.3 | % | 30.0 | % | ||||||||||||||||
| Research and development | 63.7 | % | 28.6 | % | 42.7 | % | 31.1 | % | ||||||||||||||||
| General and administrative | 51.2 | % | 30.6 | % | 43.8 | % | 24.7 | % | ||||||||||||||||
| Charges related to litigation award and government settlements | 491.9 | % | 0.0 | % | 142.2 | % | 0.0 | % | ||||||||||||||||
| Total operating expenses | 648.6 | % | 88.0 | % | 267.0 | % | 85.8 | % | ||||||||||||||||
| Income (loss) from operations | -573.0 | % | 3.9 | % | -181.7 | % | 5.9 | % | ||||||||||||||||
| Other income (expense),net | -0.3 | % | 0.0 | % | 0.0 | % | 0.0 | % | ||||||||||||||||
| Interest income | 1.7 | % | 0.5 | % | 1.3 | % | 0.4 | % | ||||||||||||||||
| Income (loss) before income taxes | -571.6 | % | 4.4 | % | -180.4 | % | 6.3 | % | ||||||||||||||||
| Income tax expense (benefit) | -29.3 | % | -0.7 | % | -14.6 | % | 0.3 | % | ||||||||||||||||
| Net income (loss) | -542.3 | % | 5.1 | % | -165.8 | % | 6.0 | % | ||||||||||||||||
| INSYS THERAPEUTICS, INC. | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (In thousands) | ||||||
| (unaudited) | ||||||
| September 30, | December 31, | |||||
| 2017 | 2016 | |||||
| ASSETS: | ||||||
| Cash and cash equivalents | $ | 35,755 | $ | 104,642 | ||
| Short-term investments | 85,891 | 78,238 | ||||
| Accounts receivable, net | 23,249 | 20,654 | ||||
| Inventories | 18,424 | 20,414 | ||||
| Prepaid expenses and other current assets | 16,544 | 5,695 | ||||
| Long-term investments | 55,514 | 53,796 | ||||
| Other non-current assets | 87,709 | 72,697 | ||||
| Total assets | $ | 323,086 | $ | 356,136 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY: | ||||||
| Liabilities | $ | 217,069 | $ | 86,547 | ||
| Stockholders' equity | 106,017 | 269,589 | ||||
| Total liabilities and stockholders' equity | $ | 323,086 | $ | 356,136 | ||
| INSYS THERAPEUTICS, INC. | ||||||||||||||||||||||||
| RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP ADJUSTED EBITDA | ||||||||||||||||||||||||
| (In thousands) | ||||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||||||||||
| Net income (loss) | $ | (166,320 | ) | $ | 2,925 | $ | (181,028 | ) | $ | 11,242 | ||||||||||||||
| Adjustments to arrive at EBITDA: | ||||||||||||||||||||||||
| Interest income | (510 | ) | (281 | ) | (1,410 | ) | (762 | ) | ||||||||||||||||
| Income tax expense (benefit) | (8,996 | ) | (379 | ) | (15,976 | ) | 523 | |||||||||||||||||
| Depreciation and amortization expense | 1,817 | 1,511 | 5,505 | 4,534 | ||||||||||||||||||||
| EBITDA | (174,009 | ) | 3,776 | (192,909 | ) | 15,537 | ||||||||||||||||||
| Non-cash stock compensation expense | 4,768 | 8,399 | 13,048 | 17,471 | ||||||||||||||||||||
| Charges related to litigation award and government settlements | 150,850 | - | 155,300 | - | ||||||||||||||||||||
| Adjusted EBITDA | $ | (18,391 | ) | $ | 12,175 | $ | (24,561 | ) | $ | 33,008 | ||||||||||||||
| INSYS THERAPEUTICS, INC. | ||||||||||||||||||||||
| RECONCILIATION OF NET INCOME (LOSS) TO NON-GAAP ADJUSTED NET INCOME (LOSS) | ||||||||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||||||||
| (unaudited) | ||||||||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||
| 2017 | 2016 | 2017 | 2016 | |||||||||||||||||||
| Net income (loss) | $ | (166,320 | ) | $ | 2,925 | $ | (181,028 | ) | $ | 11,242 | ||||||||||||
| Income tax expense (benefit) | (8,996 | ) | (379 | ) | (15,976 | ) | 523 | |||||||||||||||
| Income (loss) before income taxes | (175,316 | ) | 2,546 | (197,004 | ) | 11,765 | ||||||||||||||||
| Adjustments to arrive at Adjusted net income (loss): | ||||||||||||||||||||||
| Non-cash stock compensation expense | 4,768 | 8,399 | 13,048 | 17,471 | ||||||||||||||||||
| Charges related to litigation award and government settlements | 150,850 | - | 155,300 | - | ||||||||||||||||||
| Adjusted income (loss) before income taxes | (19,698 | ) | 10,945 | (28,656 | ) | 29,236 | ||||||||||||||||
| Less: Adjusted income tax provision | (4,363 | ) | 2,146 | (8,423 | ) | 4,438 | ||||||||||||||||
| Adjusted net income (loss) | $ | (15,335 | ) | $ | 8,799 | $ | (20,233 | ) | $ | 24,798 | ||||||||||||
| Adjusted net income per diluted share (loss) | $ | (0.21 | ) | $ | 0.12 | $ | (0.28 | ) | $ | 0.33 | ||||||||||||
CONTACT:
Media Relations
Joe McGrath
Corporate Communications
INSYS Therapeutics
480-500-3101
jmcgrath@insysrx.com
Investor Relations
Jackie Marcus or Chris Hodges
Alpha IR Group
312-445-2870
INSY@alpha-ir.com